CD19 and acute lymphoblastic leukemia: CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of relapsed or refractory pre-B acute lymphoblastic leukemia (pB-ALL), improving the prognosis for children in whom conventional therapy has failed [1,2,3].